RecruitingPhase 1NCT05184569
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
Studying Semantic dementia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peter Ljubenkov, MD
- Principal Investigator
- Peter Ljubenkov, MD, MDUniversity of California, San Francisco
- Intervention
- Verdiperstat(drug)
- Enrollment
- 64 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2022 – 2026
Study locations (5)
- UCSF Memory and Aging Center, San Francisco, California, United States
- Northwestern University, Chicago, Illinois, United States
- Mayo Clinic, Rochester, Minnesota, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Houston Methodist Hospital - Nantz National Alzheimer Center, Houston, Texas, United States
Collaborators
National Institutes of Health (NIH) · Alzheimer's Association · National Institute on Aging (NIA)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05184569 on ClinicalTrials.govOther trials for Semantic dementia
Additional recruiting or active studies for the same condition.